<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412618</url>
  </required_header>
  <id_info>
    <org_study_id>2012-245</org_study_id>
    <nct_id>NCT02412618</nct_id>
  </id_info>
  <brief_title>Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation</brief_title>
  <acronym>MMSAP</acronym>
  <official_title>A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double--‐blinded comparison of same--‐day mifepristone and misoprostol with
      misoprostol only for cervical preparation in second--‐trimester surgical abortion in 100
      women at 14 0/7--‐19 6/7 weeks gestation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women desiring abortion at gestational ages between 14 weeks 0 days and 19 weeks 6 days were
      randomized to 200-mg mifepristone or identical placebo with 400-mcg misoprostol vaginally 4-6
      hours prior to D&amp;E. Primary outcome was cervical dilation assessed by the largest Hegar
      dilator accepted without resistance. Secondary outcomes included total procedure time, and
      patient and provider perceptions. The study was powered to detect a 2-mm difference in
      cervical dilatation with 48 participants in each arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Cervical Dilation as measured by Hegar Dilator accepted with least resistance</measure>
    <time_frame>Assessed 4-6 hour following medications at time of D&amp;E procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient acceptability and assessment of pain and side effects (5-point Likert scale)</measure>
    <time_frame>intraoperative</time_frame>
    <description>5-point Likert scale given to patients following procedure once recovered from anesthesia assessing pain, side effects including nausea, vomiting, diarrhea, cramping, and if they would choose the method again or recommend to friends</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider acceptability and ease of dilation (5-point Likert)</measure>
    <time_frame>intraoperative</time_frame>
    <description>5-point Likert scale given to providers following the procedure assessing ease of procedure, ease of dilation, if they would use the same method for that patient and if they would recommend the method for other patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Induced Abortion</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Progesterone antagonist</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>Mifeprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Prostaglandin E1</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tasteless, odorless, sugar based pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women

          -  eligible for non--‐urgent D&amp;E

          -  14 0/7 weeks to 19 6/7 weeks gestation, confirmed by sonogram

        Exclusion Criteria:

          -  emergent need for D&amp;E

          -  fetal demise

          -  intolerance

          -  allergy or contraindication to mifepristone or misoprostol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 13, 2017</submitted>
    <returned>March 3, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

